Related Experiment Video
Updated: May 22, 2026
06:46
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Screening Children for Early-Stage Type 1 Diabetes
Christiane Winkler1,2, Nadine Friedl1, Renate Abt3
1Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany.
JAMA
|May 21, 2026
Summary
Population screening in children identified early-stage type 1 diabetes (T1D). Progression to clinical T1D occurred similarly in children with and without a family history, informing future therapy trials.
Area of Science:
- Pediatric Endocrinology
- Autoimmune Diseases
- Public Health Screening
Background:
- Early detection of type 1 diabetes (T1D) is crucial for interventions aimed at delaying disease onset.
- Population-based screening studies are essential for understanding the prevalence and progression of T1D in children.
Purpose of the Study:
- To estimate the prevalence of early-stage (stages 1-2) type 1 diabetes in children.
- To assess the progression rate from early-stage to clinical (stage 3) T1D.
- To evaluate the impact of family history on T1D progression.
Main Methods:
- A population-based screening study in Bavaria, Germany, involving over 220,000 children aged 1.75 to 10.99 years.
- Screening involved measuring islet autoantibodies to identify presymptomatic T1D.
- Longitudinal monitoring in specialized centers for children diagnosed with early-stage T1D.
Main Results:
- The adjusted population frequency of early-stage T1D was 0.3%, with 0.23% for stage 1 and 0.06% for stage 2.
- Five-year progression from early-stage to clinical T1D was 36.2% (annualized rate 9.6%).
- Progression rates did not significantly differ between children with and without a first-degree family history of T1D.
Conclusions:
- General population screening effectively identifies children with early-stage T1D.
- The findings support considering screening beyond genetically selected populations.
- Results provide valuable data for designing disease-modifying therapy trials for T1D.
Related Concept Videos
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...